false
0001837412
0001837412
2024-01-02
2024-01-02
0001837412
us-gaap:CommonClassAMember
2024-01-02
2024-01-02
0001837412
us-gaap:WarrantMember
2024-01-02
2024-01-02
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
January 2, 2024
SomaLogic, Inc.
(Exact name of registrant as specified in its charter)
Delaware |
|
001-40090 |
|
85-4298912 |
(State or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(IRS Employer
Identification No.) |
2945 Wilderness Place, Boulder, Colorado |
|
80301 |
(Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s telephone number, including
area code: (303) 625-9000
Not Applicable
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b)
of the Act:
Title of each class |
Trading
Symbol(s) |
Name of each exchange on which registered
|
Common
Stock, par value $0.0001 per share |
SLGC |
The NASDAQ Stock Market LLC |
Warrants, each exercisable for one share of Common Stock at an exercise price of $11.50 per share |
SLGCW |
The NASDAQ Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act
of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
| Item 7.01 | Regulation FD Disclosure. |
On January 2, 2024, SomaLogic,
Inc., a Delaware corporation (“SomaLogic”), issued a press release, a copy of which is attached as Exhibit 99.1 to this Current
Report on Form 8-K and is incorporated herein by reference.
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits
104 |
Cover Page Interactive Data File (embedded within the Inline XBRL document). |
Additional Information and Where to Find It
As previously disclosed, on
October 4, 2023, SomaLogic, Standard BioTools Inc., a Delaware corporation (“Standard BioTools”), and Martis Merger Sub,
Inc., a Delaware corporation and wholly owned subsidiary of Standard BioTools (“Merger Sub”), entered into an Agreement
and Plan of Merger, pursuant to which, among other matters, Merger Sub will merge with and into SomaLogic (the
“Merger”), with SomaLogic surviving the Merger as a wholly owned subsidiary of Standard BioTools. In connection with the
Merger and required stockholder approval, Standard BioTools filed with the Form S-4, which was declared effective by the Securities
and Exchange Commission (the “SEC”) on December 1, 2023. The Form S-4 includes a definitive joint proxy statement of
Standard BioTools and SomaLogic and also constitutes a final prospectus of Standard BioTools. The definitive joint proxy statement
was mailed or otherwise made available to stockholders of Standard BioTools and SomaLogic on or about December 4, 2023. Standard
BioTools’ and SomaLogic’s stockholders are urged to carefully read the joint proxy statement/prospectus (including all
amendments, supplements and any documents incorporated by reference therein) and other relevant materials filed or to be filed with
the SEC and in their entirety because they contain important information about the Merger and the parties to the Merger. Investors
and stockholders may obtain free copies of these documents and other documents filed with the SEC at its website at
http://www.sec.gov. In addition, investors may obtain free copies of the documents filed with the SEC by Standard BioTools at
http://investors.standardbio.com or contacting Standard BioTools’ Investor Relations department at investors@standardbio.com
or at https://investors.somalogic.com or by contacting SomaLogic Investor Relations at investors@somalogic.com.
Participants in the Solicitation
Standard BioTools, SomaLogic and
each of their respective executive officers and directors may be deemed to be participants in the solicitation of proxies from SomaLogic’s
stockholders with respect to the Merger. Information about Standard BioTools’ directors and executive officers, including their
ownership of Standard BioTools’ securities, is set forth in the joint proxy statement/prospectus, Standard BioTools’ proxy
statement for its 2023 Annual Meeting of Stockholders, which was filed with the SEC on April 28, 2023, Current Reports on Form 8-K, which
were filed with the SEC on May 3, 2023, May 15, 2023, June 16, 2023 and July 28, 2023, and Standard BioTools’ other filings with
the SEC. Information concerning SomaLogic’s directors and executive officers, including their ownership of SomaLogic securities,
is set forth in the joint proxy statement/prospectus, SomaLogic’s proxy statement for its 2023 Annual Meeting of Stockholders, which
was filed with the SEC on April 25, 2023, Current Reports on Form 8-K, which were filed with the SEC on June 6, 2023, as amended on June
14, 2023, June 9, 2023, October 4, 2023 and December 12, 2023, and SomaLogic’s other filings with the SEC. Investors may obtain
more detailed information regarding the direct and indirect interests of Standard BioTools and its respective executive officers and directors
in the Merger, which may be different than those of Standard BioTools’ stockholders generally, by reading the definitive proxy statements
regarding the Merger, which have been filed with the SEC. These documents are available free of charge at the SEC’s website at www.sec.gov,
at http://investors.standardbio.com or by contacting Standard BioTools’ Investor Relations department at investors@standardbio.com
or at https://investors.somalogic.com or by contacting SomaLogic Investor Relations at investors@somalogic.com.
No Offer or Solicitation
This Current Report on Form 8-K
and the information contained herein shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor
shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration
or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus
meeting the requirements of Section 10 of the Securities Act of 1933, as amended.
Forward-Looking Statements
This Current Report on
Form 8-K contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of
1995. Such statements are based upon current plans, estimates and expectations of the management of Standard BioTools and SomaLogic
that are subject to various risks and uncertainties that could cause actual results to differ materially from such statements, many
of which are beyond the control of Standard BioTools and SomaLogic. All statements other than statements of historical fact
(including statements containing the words “believes,” “plans,” “anticipates,”
“expects,” “estimates” and similar expressions) are statements that could be deemed forward-looking
statements, although not all forward- looking statements contain these identifying words. Readers should not place undue reliance on
these forward-looking statements. Forward-looking statements may include statements regarding the expected timing of the closing of
the Merger; the ability of the parties to complete the Merger considering the various closing conditions; and any assumptions
underlying any of the foregoing. Statements regarding future events are based on the parties’ current expectations and are
necessarily subject to associated risks related to, among other things, (i) the risk that the Merger may not be completed in a
timely manner or at all, which may adversely affect Standard BioTools’ and SomaLogic’s businesses and the price of their
respective securities; (ii) uncertainties as to the timing of the consummation of the Merger and the potential failure to satisfy
the conditions to the consummation of the Merger, including obtaining stockholder and regulatory approvals; (iii) the Merger may
involve unexpected costs, liabilities or delays; (iv) the effect of the announcement, pendency or completion of the Merger on the
ability of Standard BioTools or SomaLogic to retain and hire key personnel and maintain relationships with customers, suppliers and
others with whom Standard BioTools or SomaLogic does business, or on Standard BioTools’ or SomaLogic’s operating results
and business generally; (v) Standard BioTools’ or SomaLogic’s respective businesses may suffer as a result of
uncertainty surrounding the Merger and disruption of management’s attention due to the Merger; (vi) the outcome of any legal
proceedings related to the Merger or otherwise, or the impact of the Merger thereupon; (vii) Standard BioTools or SomaLogic may be
adversely affected by other economic, business and/or competitive factors, (viii) the occurrence of any event, change or other
circumstances that could give rise to the termination of the Merger agreement and the Merger; (ix) restrictions during the pendency
of the Merger that may impact Standard BioTools’ or SomaLogic’s ability to pursue certain business opportunities or
strategic transactions; (x) the risk that Standard BioTools or SomaLogic may be unable to obtain governmental and regulatory
approvals required for the Merger, or that required governmental and regulatory approvals may delay the consummation of the Merger
or result in the imposition of conditions that could reduce the anticipated benefits from the Merger or cause the parties to abandon
the Merger; (xi) risks that the anticipated benefits of the Merger or other commercial opportunities may otherwise not be fully
realized or may take longer to realize than expected; (xii) the impact of legislative, regulatory, economic, competitive and
technological changes; (xiii) risks relating to the value of the Standard BioTools shares to be issued in the Merger; (xiv) the risk
that post-closing integration of the Merger may not occur as anticipated or the combined company may not be able to achieve the
benefits expected from the Merger, as well as the risk of potential delays, challenges and expenses associated with integrating the
combined company’s existing businesses; (xv) exposure to inflation, currency rate and interest rate fluctuations, as well as
fluctuations in the market price of Standard BioTools’ and SomaLogic’s traded securities; (xvi) the lingering effects of
the COVID-19 pandemic on Standard BioTools’ and SomaLogic’s industry and individual companies, including on
counterparties, the supply chain, the execution of research and development programs, access to financing and the allocation of
government resources; (xvii) the ability of Standard BioTools or SomaLogic to protect and enforce intellectual property rights; and
(xviii) the unpredictability and severity of catastrophic events, including, but not limited to, acts of terrorism or outbreak of
war or hostilities, as well as Standard BioTools’ and SomaLogic’s response to any of the aforementioned factors.
Therefore, actual results may differ materially and adversely from those expressed in any forward-looking statements. For
information regarding other related risks, see the “Risk Factors” section of Standard BioTools’ most recent
quarterly report on Form 10-Q filed with the SEC on November 7, 2023, on its most recent annual report on Form 10-K filed with the
SEC on March 14, 2023 and in Standard BioTools’ other filings with the SEC, as well as the “Risk Factors” section
of SomaLogic’s most recent quarterly report on Form 10-Q filed with the SEC on November 8, 2023, on its most recent annual
report on Form 10-K filed with the SEC on March 28, 2023 and in SomaLogic’s other filings with the SEC. The risks and
uncertainties described above and in the SEC filings cited above are not exclusive and further information concerning Standard
BioTools and SomaLogic and their respective businesses, including factors that potentially could materially affect their respective
businesses, financial conditions or operating results, may emerge from time to time. Readers are urged to consider these factors
carefully in evaluating these forward-looking statements, and not to place undue reliance on any forward-looking statements. Any
such forward-looking statements represent management’s reasonable estimates and beliefs as of the date of this Current Report
on Form 8-K. While Standard BioTools and SomaLogic may elect to update such forward-looking statements at some point in the future,
they disclaim any obligation to do so, other than as may be required by law, even if subsequent events cause their views to
change.
SIGNATURE
Pursuant to the requirements of the
Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.
Date:
January 2, 2024 |
SOMALOGIC, INC. |
|
|
By: |
/s/ Ruben Gutierrez |
|
Name: |
Ruben Gutierrez |
|
Title: |
General Counsel |
Exhibit 99.1
SomaLogic Urges Stockholders to Maximize Value
of Their Investment by Voting “FOR” Pending Merger with Standard BioTools
Leading Independent Proxy Advisory Firms ISS
and Glass Lewis Both Recommend SomaLogic Stockholders Vote “FOR” Proposed Merger with Standard BioTools
BOULDER, Colo., January 2, 2024 – SomaLogic, Inc. (Nasdaq:
SLGC) (“the Company”), a leader in proteomics technology, today sent the following open letter to stockholders urging them
to vote “FOR” the value maximizing transaction with Standard BioTools.
The full text of the letter is as follows:
Dear Fellow Stockholders,
Our upcoming special meeting of SomaLogic stockholders to
vote on the merger with Standard BioTools is fast approaching. The SomaLogic Board believes that voting “FOR” the transaction
represents the best opportunity available to maximize the value of your investment in SomaLogic. The transaction is the result of a months-long,
thoughtful, fully informed review by our independent Board. Throughout that process, the Board was motivated to address the fundamental
question of what is in the best interests of SomaLogic and all its stockholders.
SomaLogic Board Determined Combination with Standard
BioTools was Superior Alternative to SomaLogic’s Standalone Plan and Best Path Forward
The choice is clear. We are confident the merger with Standard
BioTools is the right path forward – this has been confirmed by both leading independent proxy advisory firms, Institutional Shareholder
Services (“ISS”) and Glass Lewis, recommending SomaLogic stockholders vote “FOR” the pending transaction.
Benefits of Combination with Standard BioTools
·
Accelerates path to profitability and value creation through:
§
Dramatically increased scale and diversification
§
A robust and more diversified portfolio of life science tools
§
A stronger financial profile and enhanced operating leverage, with over $180 million of pro-forma combined revenue, over $500
million of cash, and only $68 million of debt
§
$80 million in anticipated run-rate cost synergies achieved by 2026
§
A combined Board and leadership team that brings together complementary teams with proven experience
·
SomaLogic stockholders will own 57% of the combined company
“The strategic rationale of combining … in order
to slow down cash burn and accelerate the path to profitability appears reasonable, particularly given the apparent overlap in the
two companies' offerings and the estimated synergies in this transaction.” – ISS1
"Generate[s] meaningful synergies and operating efficiencies…
accelerat[ing] the timeline to profitability…” – Glass Lewis1
|
SomaLogic Board Conducted Thorough, Independent and Deliberative
Board Process
·
SomaLogic publicly announced the initiation of its strategic review process in March 2023, which has provided ample opportunity
over the last ten months for any potential strategic or financial partner to emerge
·
Throughout the process, the SomaLogic Board focused on identifying strategic options that could maximize value for all SomaLogic
stockholders, including an in-depth consideration of remaining a standalone company
·
Broad outreach included direct contact with 16 parties; only one party other than Standard BioTools entered into an NDA; extensive
negotiations between the companies ensued
·
The Board conducted an independent review. An independent board member, who also has an investment in Standard BioTools, was
recused from all discussions regarding the potential transaction with Standard BioTools
“Board members … seemed appropriately qualified and
thoughtful about all available alternatives.” – ISS1
“Fairly thorough strategic review process…”
– Glass Lewis1
|
“The proposed transaction would reduce execution risks for
SomaLogic shareholders and the all-stock nature of the proposed consideration would provide SomaLogic shareholders with a majority
ownership stake in the combined company, allowing them to participate in the potential upside of the combined company.” –
Glass Lewis1
|
Madryn is Pursuing a Campaign that is Advancing its Own
Agenda at the Expense of Other Stockholders; Stockholders Should Not Let Madryn’s Misleading Claims Influence Their Votes
The future of SomaLogic and the future of your investment
is at stake. Madryn Asset Management (“Madryn”) has issued misleading public commentary regarding the merger. This opposition
is neither rooted in a desire to pursue the best path forward for the business nor to maximize value for all stockholders – rather,
they are waging a campaign to prioritize their own interests at the expense of other SomaLogic stockholders. The Board carefully evaluated
all of its alternatives – this has been confirmed by the two leading proxy advisory firms ISS and Glass Lewis – and remains
firm in its belief that this transaction represents the best opportunity to accelerate the combined company's path to profitability and
value creation, while also mitigating risks and challenges inherent in SomaLogic’s business.
Realize the Compelling Benefits of the Proposed Merger
Between SomaLogic and Standard BioTools While Protecting the Value of Your Investment: Vote “FOR” the Transaction Today
For SomaLogic to realize the benefits of this value-maximizing
transaction, stockholders holding a majority of our shares must support the deal. Your vote is critical, regardless of the number
of shares you own. Every vote counts and is critical to the future of the Company. Not voting is the same as voting against the transaction.
1
Permission to use quotes neither sought nor obtained.
Protect the value of your investment. The SomaLogic
board urges all stockholders to vote “FOR” the value maximizing transaction on the SomaLogic proxy card today. SomaLogic
stockholders are advised to discard any green proxy cards they receive from Madryn Asset Management, LP.
Thank you for your continued support.
Sincerely,
The SomaLogic Board of Directors
Robert Barchi
Thomas Carey
Troy Cox
Kathy Hibbs
Anne Margulies
Tycho Peterson
Richard Post
Jason Ryan
The Company urges all stockholders to vote "FOR" the value
maximizing transaction on the SomaLogic proxy card today. A special meeting of SomaLogic stockholders is scheduled to be held virtually
in connection with the proposed merger on January 4, 2024, at 12 p.m. ET (10:00 a.m. MT / 9:00 a.m. PT).
SomaLogic stockholders who need assistance voting or have questions
regarding the Special Meeting may contact SomaLogic's proxy solicitor, Morrow Sodali LLC, at (800) 662-5200.
The merger remains on track to close in the first quarter of 2024,
subject to approval by SomaLogic and Standard BioTools stockholders and satisfaction of other customary closing conditions.
About SomaLogic
SomaLogic is catalyzing drug research and development and biomarker
identification as a global leader in proteomics technology. With a single 55 microliter plasma or serum sample, SomaLogic can run 11,000
protein measurements, covering more than a third of the approximately 20,000 proteins in the human body. For more than 20 years SomaLogic
has supported pharmaceutical companies, and academic and contract research organizations who rely on the Company's protein detection
and analysis technologies to fuel drug, disease, and treatment discoveries in such areas as oncology, diabetes, and cardiovascular, liver
and metabolic diseases. Find out more at somalogic.com and follow @somalogic on LinkedIn.
Additional Information and Where to Find It
In connection with the merger and required stockholder approval, Standard
BioTools filed with the U.S. Securities and Exchange Commission (the "SEC") a registration statement on Form
S-4, as amended (the "Form S-4"), which was declared effective by the SEC on December 1, 2023. The Form S-4
includes a definitive joint proxy statement of Standard BioTools and SomaLogic and also constitutes a final prospectus
of Standard BioTools. The definitive joint proxy statement was mailed or otherwise made available to stockholders of Standard
BioTools and SomaLogic on or about December 4, 2023. Standard BioTools' and SomaLogic's stockholders are
urged to carefully read the joint proxy statement/prospectus (including all amendments, supplements and any documents incorporated by
reference therein) and other relevant materials filed or to be filed with the SEC and in their entirety because they contain
important information about the merger and the parties to the merger. Investors and stockholders may obtain free copies of these
documents and other documents filed with the SEC at its website at http://www.sec.gov. In addition, investors may
obtain free copies of the documents filed with the SEC by Standard BioTools at http://investors.standardbio.com or contacting
Standard BioTools' Investor Relations department at investors@standardbio.com or at https://investors.somalogic.com or
by contacting SomaLogic Investor Relations at investors@somalogic.com.
Participants in the Solicitation
Standard BioTools, SomaLogic and each of their respective
executive officers and directors may be deemed to be participants in the solicitation of proxies from Standard BioTools and
SomaLogic's stockholders with respect to the merger. Information about Standard BioTools' directors and executive officers, including
their ownership of Standard BioTools' securities, is set forth in the joint proxy statement/prospectus, Standard BioTools' proxy statement
for its 2023 Annual Meeting of Stockholders, which was filed with the SEC on April 28, 2023, Current Reports on Form 8-K,
which were filed with the SEC on May 3, 2023, May 15, 2023, June 16, 2023 and July 28, 2023, and Standard
BioTools' other filings with the SEC. Information concerning SomaLogic's directors and executive officers, including their ownership
of SomaLogic securities, is set forth in the joint proxy statement/prospectus, SomaLogic's proxy statement for its 2023 Annual
Meeting of Stockholders, which was filed with the SEC on April 25, 2023, Current Reports on Form 8-K, which were filed
with the SEC on June 6, 2023, as amended on June 14, 2023, June 9, 2023, October 4, 2023 and December
12, 2023, and SomaLogic's other filings with the SEC. Investors may obtain more detailed information regarding the direct and indirect
interests of Standard BioTools and its respective executive officers and directors in the merger, which may be different than
those of Standard BioTools' stockholders generally, by reading the definitive proxy statements regarding the merger, which have been
filed with the SEC. These documents are available free of charge at the SEC's website at www.sec.gov, at http://investors.standardbio.com or
by contacting Standard BioTools' Investor Relations department at investors@standardbio.com or at https://investors.somalogic.com or
by contacting SomaLogic Investor Relations at investors@somalogic.com.
No Offer or Solicitation
This press release and the information contained herein shall not
constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction
in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such
jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities
Act of 1933, as amended.
Forward-Looking Statements
This press release contains "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are based upon current plans, estimates and
expectations of the management of Standard BioTools and SomaLogic that are subject to various risks and uncertainties
that could cause actual results to differ materially from such statements, many of which are beyond the control of Standard BioTools and SomaLogic.
All statements other than statements of historical fact (including statements containing the words "believes," "plans,"
"anticipates," "expects," "estimates" and similar expressions) are statements that could be deemed forward-looking
statements, although not all forward-looking statements contain these identifying words. Readers should not place undue reliance on these
forward-looking statements. Forward-looking statements may include statements regarding the expected timing of the closing of the merger;
the ability of the parties to complete the merger considering the various closing conditions; and any assumptions underlying any of the
foregoing. Statements regarding future events are based on the parties' current expectations and are necessarily subject to associated
risks related to, among other things, (i) the risk that the Merger may not be completed in a timely manner or at all, which may adversely
affect Standard BioTools' and SomaLogic's businesses and the price of their respective securities; (ii) uncertainties as to the timing
of the consummation of the merger and the potential failure to satisfy the conditions to the consummation of the merger, including obtaining
stockholder and regulatory approvals; (iii) the merger may involve unexpected costs, liabilities or delays; (iv) the effect of the announcement,
pendency or completion of the merger on the ability of Standard BioTools or SomaLogic to retain and hire key personnel
and maintain relationships with customers, suppliers and others with whom Standard BioTools or SomaLogic does business,
or on Standard BioTools' or SomaLogic's operating results and business generally; (v) Standard BioTools' or SomaLogic's respective businesses
may suffer as a result of uncertainty surrounding the merger and disruption of management's attention due to the merger; (vi) the outcome
of any legal proceedings related to the merger or otherwise, or the impact of the merger thereupon; (vii) Standard BioTools or SomaLogic may
be adversely affected by other economic, business and/or competitive factors, (viii) the occurrence of any event, change or other circumstances
that could give rise to the termination of the merger agreement and the merger; (ix) restrictions during the pendency of the merger that
may impact Standard BioTools' or SomaLogic's ability to pursue certain business opportunities or strategic transactions; (x) the risk
that Standard BioTools or SomaLogic may be unable to obtain governmental and regulatory approvals required for the
merger, or that required governmental and regulatory approvals may delay the consummation of the merger or result in the imposition of
conditions that could reduce the anticipated benefits from the merger or cause the parties to abandon the merger; (xi) risks that the
anticipated benefits of the merger or other commercial opportunities may otherwise not be fully realized or may take longer to realize
than expected; (xii) the impact of legislative, regulatory, economic, competitive and technological changes; (xiii) risks relating to
the value of the Standard BioTools shares to be issued in the merger; (xiv) the risk that post-closing integration of the merger
may not occur as anticipated or the combined company may not be able to achieve the benefits expected from the merger, as well as the
risk of potential delays, challenges and expenses associated with integrating the combined company's existing businesses; (xv) exposure
to inflation, currency rate and interest rate fluctuations, as well as fluctuations in the market price of Standard BioTools' and SomaLogic's
traded securities; (xvi) the lingering effects of the COVID-19 pandemic on Standard BioTools' and SomaLogic's industry and individual
companies, including on counterparties, the supply chain, the execution of research and development programs, access to financing and
the allocation of government resources; (xvii) the ability of Standard BioTools or SomaLogic to protect and enforce
intellectual property rights; and (xviii) the unpredictability and severity of catastrophic events, including, but not limited to, acts
of terrorism or outbreak of war or hostilities, as well as Standard BioTools' and SomaLogic's response to any of the aforementioned factors.
Therefore, actual results may differ materially and adversely from those expressed in any forward-looking statements. For information
regarding other related risks, see the "Risk Factors" section of Standard BioTools' most recent quarterly report on Form 10-Q
filed with the SEC on November 7, 2023, on its most recent annual report on Form 10-K filed with the SEC on March
14, 2023 and in Standard BioTools' other filings with the SEC, as well as the "Risk Factors" section of SomaLogic's
most recent quarterly report on Form 10-Q filed with the SEC on November 8, 2023, on its most recent annual report on
Form 10-K filed with the SEC on March 28, 2023 and in SomaLogic's other filings with the SEC. The risks and
uncertainties described above and in the SEC filings cited above are not exclusive and further information concerning Standard
BioTools and SomaLogic and their respective businesses, including factors that potentially could materially affect their
respective businesses, financial conditions or operating results, may emerge from time to time. Readers are urged to consider these factors
carefully in evaluating these forward-looking statements, and not to place undue reliance on any forward-looking statements. Any such
forward-looking statements represent management's reasonable estimates and beliefs as of the date of this press release. While Standard
BioTools and SomaLogic may elect to update such forward-looking statements at some point in the future, they disclaim
any obligation to do so, other than as may be required by law, even if subsequent events cause their views to change.
Contacts
Investors
Marissa Bych
Gilmartin Group LLC
investors@somalogic.com
Media
Lyle Weston / Carly King
Joele Frank, Wilkinson Brimmer Katcher
(212) 355-4449
v3.23.4
Cover
|
Jan. 02, 2024 |
Document Information [Line Items] |
|
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
Jan. 02, 2024
|
Entity File Number |
001-40090
|
Entity Registrant Name |
SomaLogic, Inc.
|
Entity Central Index Key |
0001837412
|
Entity Tax Identification Number |
85-4298912
|
Entity Incorporation, State or Country Code |
DE
|
Entity Address, Address Line One |
2945 Wilderness Place
|
Entity Address, City or Town |
Boulder
|
Entity Address, State or Province |
CO
|
Entity Address, Postal Zip Code |
80301
|
City Area Code |
303
|
Local Phone Number |
625-9000
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Entity Emerging Growth Company |
true
|
Elected Not To Use the Extended Transition Period |
false
|
Common Class A [Member] |
|
Document Information [Line Items] |
|
Title of 12(b) Security |
Common
Stock, par value $0.0001 per share
|
Trading Symbol |
SLGC
|
Security Exchange Name |
NASDAQ
|
Warrant [Member] |
|
Document Information [Line Items] |
|
Title of 12(b) Security |
Warrants, each exercisable for one share of Common Stock at an exercise price of $11.50 per share
|
Trading Symbol |
SLGCW
|
Security Exchange Name |
NASDAQ
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
SomaLogic (NASDAQ:SLGC)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
SomaLogic (NASDAQ:SLGC)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024